{"filing":{"accession_number":"0001649094-26-000030","cik":"0001649094","ticker":"PCVX","company_name":"Vaxcyte, Inc.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"pcvx-20260713.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/pcvx-20260713.htm"},"events":[{"id":18127,"run_id":16282,"accession_number":"0001649094-26-000030","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The filing discloses the appointment of John Markels to the Board as a Class II director effective July 16, 2026, with concurrent appointment to the Audit Committee and Compensation Committee. While the section also mentions Heath Lukatch's retirement, the principal disclosed action centers on the new director appointment and his committee assignments. Board composition changes are material to investors assessing governance and oversight.","company_name":"Vaxcyte, Inc.","ticker":"PCVX","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":[{"id":16843,"accession_number":"0001649094-26-000030","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of John Markels to the Board as a Class II director effective July 16, 2026, with concurrent appointment to the Audit Committee and Compensation Committee. While the section also mentions Heath Lukatch's retirement, the principal disclosed action centers on the new director appointment and his committee assignments. Board composition changes are material to investors assessing governance and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:07:55.036441+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16843,"accession_number":"0001649094-26-000030","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of John Markels to the Board as a Class II director effective July 16, 2026, with concurrent appointment to the Audit Committee and Compensation Committee. While the section also mentions Heath Lukatch's retirement, the principal disclosed action centers on the new director appointment and his committee assignments. Board composition changes are material to investors assessing governance and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:07:55.036441+00:00","company_name":"Vaxcyte, Inc.","ticker":"PCVX","filing_date":"2026-07-15"}]}